National Trends of Antiparkinsonism Treatment in Taiwan: 2004-2011 (original) (raw)
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010
Mitsutoshi Yamamoto
PloS one, 2014
View PDFchevron_right
Initial Medication in Patients of Newly Diagnosed Parkinson’s Disease in Taiwan
Yi-chu Liao
PLoS ONE, 2014
View PDFchevron_right
Impact of the Publication of Chinese Treatment Guideline on the Initial Therapy in Parkinson's Disease in Beijing
Fortune Journals
View PDFchevron_right
Pharmacological Treatment Pattern and Comorbidities in Parkinson’s Disease Outpatients at Dr. Hasan Sadikin General Hospital Bandung in 2013–2018
Elke Feliciana
Althea Medical Journal, 2019
View PDFchevron_right
Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study
Jou-Wei Lin
Journal of the Formosan Medical Association, 2016
View PDFchevron_right
Treatment of Advanced Parkinsonʼs Disease in the United States
Marcy Tarrants
Clinical Drug Investigation, 2010
View PDFchevron_right
Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease: An Exploratory Case-Control Study
Lucia Ameghino
Clinical Neuropharmacology, 2018
View PDFchevron_right
Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients
Marco Cosentino
Pharmacoepidemiology and drug safety, 2002
View PDFchevron_right
Patterns and Determinants of Prescribing for Parkinson’s Disease: A Systematic Literature Review
Khalid Orayj
Parkinson's Disease, 2019
View PDFchevron_right
gUIDELINE COMPARISON AND ASSESSMENT OF PRESCRIbINg TRENDS IN PARKINSON’S DISEASE
Marise Gauci
2019
View PDFchevron_right
A Prospective Study of the Drug Prescribing Rate and Pattern and Assessment of Adverse Drug Reactions in Patients with Idiopathic Parkinson Disease in a Tertiary Care Hospital
Am Jour of Phytomed & Clinical Therapeut
American Journal of Phytomedicine and Clinical Therapeutics (AJPCT), 2014
View PDFchevron_right
Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy
Giuseppe Meco
Acta Neurologica Scandinavica, 2009
View PDFchevron_right
Motor and non-motor symptoms of 1453 patients with Parkinson's disease: Prevalence and risks
Taku Hatano
Parkinsonism & Related Disorders, 2013
View PDFchevron_right
Trends in inpatient antiparkinson drug use in the USA, 2001-2012
Donald Mattison
European journal of clinical pharmacology, 2015
View PDFchevron_right
Prescribing Pattern for Parkinson’s Disease in Indian Community before Referral to Tertiary Center
Nitish L Kamble
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
View PDFchevron_right
Prescribing patterns of antiparkinsonian agents in Europe
Cristina Sampaio
Movement Disorders, 2010
View PDFchevron_right
Postural Disorders and Antiparkinsonian Treatments in Parkinson Disease
Lucia Ameghino
Clinical Neuropharmacology, 2018
View PDFchevron_right
National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease
Johan Lökk
Journal of Multidisciplinary Healthcare, 2013
View PDFchevron_right
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
Emma McIntosh
Lancet, 2014
View PDFchevron_right
Review of Medicine Utilization for Parkinson's Disease Management: The Bulgarian Perspective
Guenka Petrova
Journal of Public Health Research, 2021
View PDFchevron_right
Variations in Incidence and Prevalence of Parkinson's Disease in Taiwan: A Population-Based Nationwide Study
Chih-Ching Liu
Parkinson's disease, 2016
View PDFchevron_right
Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease
Robert Rubens
Clinical Neuropharmacology, 2018
View PDFchevron_right
Costs of Parkinson’s Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study
Giuseppe Spiga
Neurodegenerative Diseases, 2010
View PDFchevron_right
Drug management of Parkinson's disease
Asha Kishore
Canadian Family Physician Medecin De Famille Canadien, 1996
View PDFchevron_right
Linking Individual Patient Data to Estimate Incidence and Prevalence of Parkinson's Disease by Comparing Reports of Neurological Services and Pharmacy Prescription Refills at a Nationwide Level
Dániel Bereczki
Frontiers in Neurology
View PDFchevron_right
Parkinson's disease severity and use of dopaminergic medications
Michael Aminoff
Parkinsonism & Related Disorders, 2015
View PDFchevron_right
Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease
Li-nien Chien
Parkinsonism & Related Disorders, 2019
View PDFchevron_right
Management of Parkinson's Disease
Angelo Antonini
European Neurological Review, 2007
View PDFchevron_right
The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study
Clelia Pellicano
European journal of medical research, 2013
View PDFchevron_right
Pharmacotherapy for Parkinson's disease
Jack Chen
Pharmacotherapy, 2007
View PDFchevron_right
A Roadmap for Future Parkinson's Pharmacogenomics in Asia
Muhammad Fikhi akbar
Frontiers in Aging Neuroscience
View PDFchevron_right
Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review
Edna Schechtman
Neurology
View PDFchevron_right
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
A Jon Stoessl
Movement Disorders
View PDFchevron_right